Papyrus Australia moved its banana-fibre technology into early commercialisation during FY26, signing an estimated $4.2 million TBS supply contract and delivering commercial-scale samples. But the company ended the year with $257,077 cash, negative equity and an auditor-flagged material uncertainty over its ability to continue as a going concern.
- Estimated $4.2 million TBS contract over 3.5 years
- Commercial-scale Collar Keeper samples delivered for acceptance testing
- FY26 loss narrowed to $1.48 million from $2.83 million
- Cash fell to $257,077 while current liabilities reached $1.38 million
- Post-year-end funding includes $200,000 and $500,000 loan arrangements
Commercial progress meets a severe funding test
Papyrus Australia Ltd (ASX:PPY) has reached the point its banana-fibre technology was designed for: commercial product development. The company signed a 3.5-year manufacture and supply contract with TBS Mining Solutions for biodegradable Collar Keeper® products, with estimated revenue of approximately $4.2 million subject to the contract terms, acceptance testing and commercial launch.
The catch is visible in the balance sheet. Papyrus finished FY26 with $257,077 in cash, of which $228,168 was restricted in Egypt, against $1.38 million of current liabilities. The group reported a net liability position of $323,287, reversing net assets of $307,713 a year earlier. Its auditor, BDO, said there was a material uncertainty that could cast significant doubt on the group’s ability to continue as a going concern.
TBS samples still require acceptance
During the June quarter, Papyrus supplied TBS with its first commercial-scale samples, produced using third-party board-forming and conversion equipment. Testing generated performance data that is being used to refine the board’s attributes, and the two parties agreed to produce and test another batch as part of the acceptance process.
That means the headline contract is not yet equivalent to booked revenue. Papyrus says both parties remain committed to development and commercial launch, but the product must still clear the remaining acceptance work before the company can move into sustained production for TBS.
Adelaide and Vietnam pathways advance
The Adelaide Rapid Prototyping and R&D Facility moved from installation into full operation, with its moulding line and prototype pulp preparation system commissioned. The facility produced its first moulded trays and supported pulp and board trials, including work connected to the TBS product.
Papyrus also executed a binding board production contract with a Vietnam-based paperboard manufacturer, satisfying the first milestone under the TBS contract. The arrangement envisages Australian-produced pulp being converted into paperboard jumbo rolls in Vietnam. Two initial trial runs will be completed at a fixed cost, while longer-term pricing remains to be negotiated after those trials.
Loss narrows, but cash use accelerates
FY26’s loss after tax narrowed to $1.48 million from $2.83 million, helped by the absence of the $1.01 million impairment recorded in FY25. Other income rose to $636,810, including $418,758 from the R&D Tax Incentive and $187,602 from the Industry Growth Program grant.
That improvement did not translate into a stronger cash position. Operating cash outflow increased to $1.12 million from $420,177, while the company spent $329,714 on plant and equipment. Papyrus received $747,000 from share issues and $500,000 from convertible notes during the year, but cash still declined by $48,252.
More funding required for the scale-up
The going-concern assessment depends partly on Papyrus raising additional capital or receiving funds from option exercises. After year-end, the company disclosed an unsecured loan facility of up to $200,000 with interest of 1.5% a month and separately executed agreements for a further $500,000 from sophisticated and related-party investors. The latter arrangements carry 1.5% monthly interest initially and are intended to convert into unsecured convertible notes subject to shareholder approval.
Those arrangements may provide working capital, but they also add financing obligations and potential dilution to a company whose ordinary share count had already risen to 648.9 million by 30 June. The immediate operational test is therefore two-sided: Papyrus must complete TBS acceptance and bring its Adelaide scale-up pathway into operation before its financing runway becomes the more important story.
Bottom Line?
Papyrus has moved beyond laboratory validation, but commercial launch and fresh funding must arrive before the balance sheet becomes the decisive constraint.
Questions in the middle?
- Will the additional TBS sample batch satisfy acceptance requirements and unlock commercial production?
- Can Papyrus establish its Adelaide scale-up facility without requiring another heavily dilutive funding round?
- How quickly will the post-year-end loan arrangements convert into usable cash, and what will they cost shareholders?